A second allograft was offered to 58 relapsed AML patients after conditioning with fludarabine 90-150 mg/m 2 and thiotepa 15 mg/kg, in most cases with active disease. Median age was 53 years (range 23-69), median time to relapse after the first allo-SCT was 326 (47-2189) days and median follow-up was 6.7 years. GVHD prophylaxis consisted mainly of CsA and alemtuzumab. Response rates at 1 month were CR in 50 and persistent disease in 3/53 evaluable patients. At 3 years, the relapse incidence (95% confidence interval) was 56 (45-71)%, the TRM 31 (21-46)%, the OS rate was 18 (9-29)% and the EFS rate was 13 (5-23)%. OS improved with younger patient age, longer relapse-free interval after the first allo-SCT and the development of chronic GVHD. Patients p65 years old who relapsed 412 months after the first allograft (n ¼ 20) had a 3-year OS rate of 41 (19-62)%. Conventional cytogenetics and FLT3 mutation status did not affect outcome. Our regimen is feasible and provides at least for a subgroup of patients with AML recurrence after allo-SCT a reasonable therapeutic option in an otherwise fatal situation. Further modifications and a better understanding of the underlying biology could help lower the risk of relapse. 
INTRODUCTION
For patients with AML, relapsing after allo-SCT prognosis is very poor. A second allograft is currently the only therapeutic approach capable of inducing long-term remissions in patients who cannot be salvaged with DLI. 1, 2 This approach has, however, two main limitations. First, many of these patients cannot tolerate a second allo-SCT because of accumulated organ toxicities and opportunistic infections, which increase the risk for TRM and severe GVHD. 3, 4 Second, despite high TRM and GVHD rates, relapse remains the main cause of death in this very high-risk patient population. [5] [6] [7] [8] The concept of allo-SCT with reduced-intensity conditioning (RIC) is based on the notion that the GVL contributes significantly to the curative potential. This permits dose reductions of preparative chemotherapy or radiation with a lower overall toxicity. 9 In 2008, we reported the results of a phase II RIC trial using fludarabine 5 Â 30 mg/m 2 and thiotepa 3 Â 5 mg/kg in patients with recurrent or persistent haematological malignancies after a previous auto-or allo-SCT. 3 In this series, a TRM (95% confidence interval) of 29 (14-44)% at 2 years despite heavy pretreatment demonstrated the feasibility of our regimen, but the low number of patients in each diagnostic subgroup and the relatively short follow-up precluded a thorough evaluation of efficacy.
Here we analyse the long-term outcome of a larger, homogeneous patient cohort with AML at relapse after first allo-SCT treated in a similar manner.
PATIENTS AND METHODS Patients
Included in this retrospective analysis are all 58 patients who received a second allograft at our institution between January 2000 and December 2010 due to AML relapse after the first allo-SCT. The first 18 of these patients also formed the AML patient subgroup in the first report of this regimen in 2008. 3 A second allo-SCT was performed for fit patients failing treatment with DLI (previously given to 39/58 patients with a starting dose of 0.5-1 Â 10 6 CD3 þ cells per kg body weight) or deemed unsuitable for such because of active GVHD or high leukaemic burden. The data analysis was in September 2011. All patients gave written informed consent for treatment and data evaluation according to the declaration of Helsinki.
Patient characteristics are listed in Table 1 . Only 4/58 patients were transplanted in CR. At least one cycle of induction chemotherapy had been given pretransplant to 29/58 patients, with chemoresistant disease in 18/29 and chemosensitivity in 10/29 (defined as blast reduction X50%), while one patient was not evaluated. The remaining patients, mostly having AML with low blast counts or related to myelodysplasia, underwent only mild therapies prior to the second conditioning, like 5-day courses of azacytidine or chemotherapy with cytarabine and/or anthracyclines or topotecan in reduced doses directly prior to conditioning.
Conditioning regimens used for the first allo-SCT were BUCY (n ¼ 30), fludarabin/BCNU/melphalan (n ¼ 27) 10 and the same fludarabine/thiotepa regimen in one patient with previous auto-SCT for a Hodgkin lymphoma. 3 Median time to relapse after the first allo-SCT was 326 days (range 47-2189), with 32/58 patients relapsing within one year.
Donors, grafts and transplant characteristics
HLA class I antigens were typed by serology or intermediate resolution DNA techniques (two digits, n ¼ 50) until April 2009 and with highresolution DNA techniques thereafter (four digits, n ¼ 8). HLA class II antigens were typed by high resolution DNA techniques (four digits). HLAmatched (A, B, DRB1 and DQB1) unrelated donors were preferred for the second allo-SCT (n ¼ 56, 41/56 HLA-identical, 14/56 with one mismatch, 1/ 56 with two mismatches), but sibling donors (n ¼ 2) were employed for a patient with syngeneic first allo-SCT and another patient without an unrelated donor available. In 56/58 cases we found a donor different than that employed for the first allo-SCT. Median donor age was 33 years (range 18-56). All patients were transplanted with G-CSF-mobilised unmanipulated peripheral blood stem cells except for one, who received BM. Thirtynine patients received a graft from a same sex donor, whereas 19 patientdonor pairs were from different sexes, including 11 pairs of male recipient and female donor. Fourty-four patients were at risk for CMV reactivation (CMV positive donor or recipient, Table 1 ).
Conditioning regimen and GVHD prophylaxis
Patients transplanted until June 2005 (n ¼ 18) received fludarabine 30 mg/m 2 on days À 8, À 7, À 6, À 5, À 4 (total dose 150 mg/m 2 ) as an 1 h infusion and thiotepa 5 mg/kg on days À 7, À 6, À 5 (total dose 15 mg/kg) 2 h after the end of fludarabine as a 2 h infusion. In July 2005, the fludarabine dose was reduced to 30 mg/m 2 given on the same 3 days À 6, À 5, À 4 (total dose 90 mg/m 2 , n ¼ 40) as thiotepa to reduce infectious complications. 3 The unmanipulated graft was infused on day 0. The GVHD prophylaxis initially consisted of CsA 2.5 mg/kg every 12 h starting on day À 3 (trough level 250-350 ng/mL), MTX 5 mg/m 2 on days þ 1, þ 3, þ 6 and rabbit ATG (Fresenius, Gräfelfing, Germany) 20 mg/kg on days À 2, À 1 (total dose 40 mg/kg) (n ¼ 4, all with unrelated donors). Owing to severe toxicity, this was soon replaced by CsA and alemtuzumab (MabCampath, Schering, Berlin, Germany) 40 mg i.v. (n ¼ 13 patients received 40 mg alemtuzumab), as described previously. 3 In July 2005, the Therapy had been administered for breast cancer (n ¼ 1), Hodgkin lymphoma (n ¼ 2), seminoma (n ¼ 1), ALL (n ¼ 1) and previous AML (n ¼ 1). Four of these cases were MDS-related, as defined by the presence of multilineage dysplasia in three patients and by a complex karyotype in the fourth. Excluded are three patients, in whom the 1st allo-SCT was performed due to MDS (n ¼ 2) or myelofibrosis (n ¼ 1) before the diagnosis of AML.
f HLA matched for HLA-A, -B, -DR and -DQ.
g One patient with a first allo-SCT from a syngeneic donor and a second allo-SCT from an MRD as well as one patient with the same MRD in the first and second allo-SCT.
h Details in the main text.
alemtuzumab dose was reduced to 20 mg given i.v. as 10 mg/day on days À 2 and À 1 (n ¼ 5), and since July 2006, we have been administering a single dose of 10 mg i.v. on day À 1 for HLA-matched donors or lack of serious GVHD after the first allo-SCT (n ¼ 28) and 20 mg as before for transplants from HLA-mismatched donors or with severe GVHD after the first SCT (n ¼ 6). 11 Mycophenolate mofetil (MMF) 2 g/d starting on day þ 1 was added to CsA and alemtuzumab in one case because of extensive chronic GVHD (cGVHD) at the time of relapse. In the single case of second allo-SCT from the same sibling donor as in the first allo-SCT, alemtuzumab was omitted and the immunosuppression was with CsA and MMF only (Table 1 ). In patients without GVHD, MMF was usually tapered from day þ 30 and discontinued before day þ 100, whereas CsA was usually tapered from day þ 60 and discontinued around day þ 120.
Severity scoring of GVHD Acute GVHD (aGVHD) was graded according to the IBMTR criteria. 12 Chronic GVHD was characterised as limited or extensive according to Schulman et al. 13 Statistical analysis OS time was calculated from the date of the second SCT to date of death from any cause. EFS time was calculated from the date of the second SCT to the date of death from any cause or relapse/progression, whichever occurred first. If the event of interest was not observed, observations were censored at the latest date of documented survival or survival without relapse/progression respectively. OS and EFS rates were estimated with the Kaplan-Meier method.
Time to TRM was measured from the date of the second SCT until death, without evidence of relapse/progression. Time to relapse/progression and time to GVHD (acute and chronic) was calculated from the date of the second SCT until the date of the documented relapse/progression or GVHD. The probability of TRM, relapse/progression and GVHD was estimated by the cumulative incidence function, considering relapse/ progression as competing event for TRM, and considering death without relapse/progression and death without GVHD as competing event for relapse/progression and GVHD, respectively.
The effects of age (p40, 41-50, 51-65, 465 years), time to relapse after first allo-SCT (p6, 6-12, 12-24, 424 months), cGvHD after first allo-SCT (no, yes), cytogenetic risk (low/intermediate, high), monosomal karyotype (no, yes), FLT3 mutations at initial diagnosis for patients with intermediate cytogenetic risk (no, yes), induction chemotherapy before second SCT (no, yes), time of second SCT (until July 2005, after July 2005), LDH before 2nd SCT (4300, p300 U/L), remission status before first SCT, donor change (matched-related to matched-unrelated vs matched-unrelated to different matched-unrelated) and unfavourable sex constellation with female donor to male recipient (no, yes) on OS were analysed with Cox regression models. Cutoff points for classifying patients into prognostic groups were predefined. Univariate analyses of the factors were performed, evaluating their effects separately. In multiple regression analyses, those factors revealing a prognostic effect in the univariate analysis with Pp0.05 were analysed simultaneously.
The effects of GVHD (acute and chronic) on OS were analysed with Cox regression models with GVHD as time-dependent covariate. This was done in univariate analysis, and in multivariate analysis including, additionally, the baseline factors with an effect on OS for adjustment.
All analyses were preplanned before data inspection and done using SAS V9.2 (SAS Institute GmbH, Frankfurt, Germany).
RESULTS

Engraftment, chimerism and transfusion needs
Stable engraftment with an ANC X0.5 Â 10 9 /L and X20 Â 10 9 /L platelets occurred in 53/58 evaluable patients after a median time period of 16 (range 11-37) and 12 days (range 17-66), respectively. Five patients were not evaluable because of early death, whereas one additional patient remained platelet transfusion-dependent until his death on day þ 146. G-CSF from day þ 7 until neutrophil regeneration was given to patients transplanted until March 2004 (n ¼ 10). After 1 month, 35/58 patients had achieved full donor chimerism (assessed with amplified microsatellite DNA in blood for 1 and in BM for 34 patients), 17/58 patients had mixed chimerism and 6 patients were not evaluable. No secondary graft failure occurred.
Nonhaematologic adverse events and infectious complications
The treatment was generally well-tolerated without unusual toxicities or infectious complications. We observed no notable differences to what we have already published. 3 
GVHD
We observed grade II aGVHD in 13/58 patients and grade III-IV aGVHD in 11/58 patients (Table 2), the latter with skin (n ¼ 10), gut (n ¼ 5) and/or liver (n ¼ 5) involvement. Two patients died of aGVHD grade IV with concomitant infections on days þ 56 and þ 142.
Fourty-three (43/58) patients were evaluable for cGVHD. In 22/43 no cGVHD was observed, 5/43 had limited cGVHD and 16/ 43 extensive ( Table 2) . At 3 years, the incidence of cGVHD was 48.8 (36.0-66.3)% and the incidence of extensive cGVHD 37.2% (25.2-54.9, Table 3 ). No increase in the cGvHD incidence could be observed after the protocol amendment in 2005 (41 vs 64% before the amendment). One cause of stupor and death with pneumonia at day þ 52 as well as one case of early multiorgan failure in a patient with uncontrolled disease and death at day þ 18. Cumulative risks for aGVHD refer to day þ 100 post allo-SCT.
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Response, survival, relapse/progression and causes of death Best responses following second allo-SCT were CR (n ¼ 50) and persistent disease (n ¼ 3), whereas five patients were not evaluable because of early death due to infectious complications and multiorgan failure.
Median follow-up time was 6.7 years. Eight patients were alive at last follow-up (minimum 1.1 years, maximum 11.5 years). Six of them are in continuous CR, one relapsed 17 months after the second allo-SCT, which was from a sibling donor, and is currently in CR 9 months after a third allo-SCT from an unrelated donor, and the last one is in CR after successful treatment of her relapse at 1 year with DLI and azacytidine. At 3 years, the OS rate is 17.7 (9.0-28.9)% and the EFS rate 12.5% (5.4-22.9, Table 3 and Figure 1) .
Overall there were 50/58 deaths, including 15 deaths in the first 100 days. Mortality was mainly attributable to relapse (34/50) and secondarily to nonrelapse causes (16/50). Reasons for TRM were infection (n ¼ 10), early toxicity (n ¼ 2), aGVHD grade IV (n ¼ 2), cGvHD (n ¼ 1) and secondary malignancy (n ¼ 1, Table 2 ). At 3 years, the relapse incidence was 56.1 (44.5-70.7)% and the TRM 31.4 (21.4-46.1%, Table 3 and Figure 1 ). Salvage treatment was primarily with DLI in 22/33 patients with relapse, mostly combined with azacytidine.
14 Furthermore, two patients received a third allo-SCT, but none of them survived at the time of data analysis. Finally, prophylactic DLI were given to two patients with complete donor chimerism by the decision of the attending physician.
Main prognostic factors for OS were patients' age and the time to relapse after the first allo-SCT. Advanced age increased the patients' risk of death (P ¼ 0.006) with a hazard ratio of 3.85 (1.62-9.14) for patients aged 465 years compared with those aged p40 years (Table 4 and Figure 2 ). No patient older than 65 years survived over the long term, whereas the OS rate at 3 years was 22.4 (11.3-35.7)% for patients p65 years old. In addition, the risk of death was inversely related to the relapse-free interval after the first allo-SCT (P ¼ 0.03). A relapse-free interval of 412 months conferred a median OS of 11.2 (six-not estimable) months and reduced the risk of death by approximately half compared with a relapse-free interval p12 months (median OS 4.8 (2.2-7.7) months, Table 4 and Figure 2 ). Patients with both favourable prognostic factors (p65 years old and a relapse-free interval 412 months after first allo-SCT, n ¼ 20) had an OS rate of 40.9 (18.5-62.3)% and an EFS rate of 25.7 (8.6-47.2)% at 3 years (Figure 2) .
Chronic GVHD after the second SCT also conferred a better prognosis with respect to OS. After adjustment for age and time to relapse after first allo-SCT, the hazard ratio for patients developing cGvHD was 0.41 (0.17-0.97, P ¼ 0.044, Table 5 ).
We had cytogenetic data available on 56/58 patients, but observed no prognostic effect of adverse 15 or monosomal 16 karyotype on OS after second allo-SCT. Similarly, FLT3 mutations in 7 of 19 patients with intermediate risk karyotype subjected to molecular analysis and the other examined factors were not significantly associated with a worse prognosis ( Table 4) .
DISCUSSION
In this retrospective analysis, we report the outcome of 58 consecutive patients receiving a second allograft with RIC for relapsed AML. These patients pose a special therapeutic challenge, since they are especially prone to TRM due to heavy pretreatment, while also carrying a very high risk of relapse.
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We tried to address both problems by developing a novel RIC protocol with fludarabine and thiotepa aiming to combine efficacy with low organ toxicity. 3 Thiotepa was chosen because it is a welltolerated alkylator with potent antileukaemic as well as stem-cell toxic activity, [17] [18] [19] whereas fludarabine is as immunosuppressive as CY, but less toxic and enhances alkylator-induced damage by inhibiting DNA repair. 20, 21 Our regimen facilitated engraftment in all our evaluable 53 patients without subsequent graft failures. Complete donor chimerism was achieved by 35/52 evaluable patients at one month. Despite multiple pretreatments and active disease in most patients, the second allo-SCT was relatively well-tolerated with a TRM of 31% at 3 years, mainly attributable to infections. This result confirms our earlier report based on less mature data from a diverse patient population treated similarly. 3 Furthermore, it resembles data from more recent series incorporating less intensive conditioning protocols, 6 but appears slightly better than the TRM with myeloablative regimens, either TBI-based or BUCY. 5, 7, 8 Early disease control was very satisfactory with 50/53 evaluable patients achieving CR at 1 month. Nevertheless, as in other series, most patients subsequently relapsed and died from their leukaemia. At 3 years our patients' relapse incidence was 56% and the OS rate 18%, similar to the results of some series, 8, 22 but worse than the 40-50% relapse rate and 30% OS rate observed by other investigators after myeloablative or RIC. [5] [6] [7] 23 A higher relapse incidence has been noted with the use of RIC regimens in some studies, 6 but there are exceptions. 23 Other possible causes for our series' high relapse rate are our patients' advanced median age, 6 early relapse p12 months after first allo-SCT in 32/58 patients, 7 and the fact that only 4/58 patients were transplantated in CR. 1, 5 Reasons for the latter were treatment failure in 22/26 evaluable patients receiving salvage chemotherapy before second conditioning as well as our intention to avoid excessive toxicity in patients with low leukaemic burden or myelodysplasia-related AML, who are often refractory to cytotoxic therapies. In our series, the donor was systematically changed for the second, but the influence of this strategy cannot be assessed due to the lack of control group. The outcome appears similar regardless of the donor type, related or unrelated, employed for the first allo-SCT. Similar to other reports, a main prognostic factor for OS was the time to relapse after the first allo-SCT with a median OS of 4.8 months after second allo-SCT for patients relapsing at p12 months. 6, 22 Supportive care alone confers a median OS of 4 months for relapsed allografted patients, 24 thus our data support the recommendation of a second allograft as a viable option for patients relapsing later than 1 year post transplant. 15 Patient age was another significant prognostic factor and correlated inversely with survival. Notably, patients in our series p65 years old with a relapse-free interval 412 months after the first allograft had an OS rate of 41% at 3 years. With these promising results, therapeutic nihilism for such patients is not warranted. On the other hand, except in special circumstances, a second allograft with our regimen is not warranted for patients 465 years old given the poor outcome in this age group.
In the 43 evaluable patients, the development of cGVHD after the second allograft correlated with longer OS. A similar observation in other series 8, 22 underlies the recommendation to reduce GVHD prophylaxis before second allo-SCT, in order to improve outcome. 1 We amended our protocol in July 2005 accordingly by reducing the alemtuzumab dose, but did not observe any increase in cGVHD or improvement in OS thereafter. Consequently, we intend to replace alemtuzumab with a reduced dose of rabbit ATG (Fresenius) resulting in a possibly milder immunosuppression post transplant. 25 Furthermore, we plan to prospectively study an intensified-conditioning regimen for patients up to 65 years old with addition of treosulfan, taking into account the aforementioned negative impact of age and, possibly, RIC 6 on outcome, as well as the active disease most of our patients have at the time of second allo-SCT.
The biology of AML failing allo-SCT is poorly understood. The lack of significant association between conventional cytogenetics or FLT3 mutations and prognosis in our series, contrary to AML cohorts after first allo-SCT, 26, 27 suggests the selection of other adverse biologic factors in these very high-risk patients. Such defects, like the loss of HLA heterozygosity in leukaemic blasts, were recently demonstrated by more sensitive methods, such as genome-wide profiling. [28] [29] [30] In summary, our report confirms the feasibility of our regimen in offering a second allograft to AML patients after failure of a previous allo-SCT, but also highlights the major obstacles to cure in this particular patient population. The outcome could be further improved through fine-tuning of treatment intensity and GVHD prophylaxis as well as better understanding of the biology underlying allo-SCT failure in AML. Moreover, the high CR rate of our patients followed by a high incidence of relapse suggests that post transplant interventions, like vaccines, preemptive treatment of minimal residual disease or tyrosine kinase inhibitors could also be beneficial.
